- Home
- EVOK vs THAR Comparison
EVOK vs THAR Comparison
Compare EVOK & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- THAR
- Stock Information
- Founded
- EVOK 2007
- THAR 2017
- Country
- EVOK United States
- THAR United States
- Employees
- EVOK N/A
- THAR N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- THAR Health Care
- Exchange
- EVOK Nasdaq
- THAR Nasdaq
- Market Cap
- EVOK 4.2M
- THAR 4.0M
- IPO Year
- EVOK 2013
- THAR 2022
- Fundamental
- Price
- EVOK $2.45
- THAR $1.25
- Analyst Decision
- EVOK
- THAR Strong Buy
- Analyst Count
- EVOK 0
- THAR 1
- Target Price
- EVOK N/A
- THAR $17.00
- AVG Volume (30 Days)
- EVOK 27.3K
- THAR 135.2K
- Earning Date
- EVOK 03-13-2025
- THAR 05-08-2025
- Dividend Yield
- EVOK N/A
- THAR N/A
- EPS Growth
- EVOK N/A
- THAR N/A
- EPS
- EVOK N/A
- THAR N/A
- Revenue
- EVOK $10,249,415.00
- THAR N/A
- Revenue This Year
- EVOK $99.03
- THAR N/A
- Revenue Next Year
- EVOK $60.15
- THAR N/A
- P/E Ratio
- EVOK N/A
- THAR N/A
- Revenue Growth
- EVOK 97.84
- THAR N/A
- 52 Week Low
- EVOK $2.40
- THAR $1.20
- 52 Week High
- EVOK $12.32
- THAR $7.13
- Technical
- Relative Strength Index (RSI)
- EVOK 26.36
- THAR 32.14
- Support Level
- EVOK $2.51
- THAR $1.20
- Resistance Level
- EVOK $2.81
- THAR $1.47
- Average True Range (ATR)
- EVOK 0.29
- THAR 0.15
- MACD
- EVOK -0.02
- THAR -0.01
- Stochastic Oscillator
- EVOK 8.12
- THAR 2.04
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.